SecBot SecBot

PMN

ProMIS Neurosciences Inc.
Nasdaq· Pharmaceutical Preparations· Inc. Z4· CIK 0001374339 Biotech & Drug Discovery
$8.06 −0.28 (−3.36%)
Oct 26 4:00 PM ET · prev $8.34
Market cap
$80.5M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 10
in 14 days · EPS est. −$1.82
1 year
−29.9%
from $11.50 · Oct 27
30 days
−24.3%
from $10.65
52-week range
$6.76–24.79
−67% from high · low Nov 28
Avg volume 20D
25.9K
Oct 1 spike 102.1K
Short interest
🔒 Subscribers only
Insider net
+$8.6M
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $8.6M at an average $12.17. No open-market sales. Price is 34% below their cost.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better.

  • TrendDOWNTREND

    31% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCTRIM56,045$737.6K
UBS Group AGTRIM691$9.1K
JANUS HENDERSON GROUP PLCNEW1,292,757$16.4M
Federation des caisses Desjardins du QuebecNEAR_EXIT10$127.00
TD Waterhouse Canada Inc.NEAR_EXIT5$65.00
CITADEL ADVISORS LLCDOUBLED170,079$72.3K
TD Waterhouse Canada Inc.DOUBLED940$422.00
ROYAL BANK OF CANADADOUBLED5,487$5.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy2Buy9Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 14, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 29, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 28, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Jul 27, 2026Chardan Capital
INITIATE
INITIATEBuy
Jul 8, 2026Roth Capital
INITIATE
INITIATEBuy
Jun 30, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$8.6M
bought · 4 insiders
$0
sold · 0 insiders
−33.8%
vs their $12.17 cost
DateInsiderTypeValue
Oct 5, 2026
Rubino Ivana
Chief Commercial Officer
AWARD80,000 sh
Aug 5, 2026
Kaplan Johanne
Chief Development Officer
BUY$30.3K
May 20, 2026
Alex Slanix Paul
Director
AWARD11,000 sh
May 20, 2026
Mandel-Brehm Josh
Director
AWARD11,000 sh
May 20, 2026
Shafmaster Madge K.
Director
AWARD11,000 sh
May 20, 2026
Williams Eugene
Director
AWARD11,000 sh
May 20, 2026
WYMAN WILLIAM W
Director
AWARD11,000 sh
May 20, 2026
Kaplan Johanne
Chief Development Officer
AWARD50,000 sh

Earnings setup

Estimates
Nov 10
reports in 14 days
−$1.82
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.82-$1.85–-$1.79+15.1%$0.00
Next Q-$1.95-$2.05–-$1.86+18.1%$0.00
Current FY-$7.36-$7.49–-$7.23+10.7%$0.00
Next FY-$5.48-$9.48–-$3.44+2.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Ivana Rubino filed a Form 3 initial statement of beneficial ownership upon becoming Chief Commercial Officer of ProMIS…
3 — Impact 2/10
Oct 6, 2026 Press
ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino…
Impact 3/10
Oct 6, 2026 Announcement
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical developm
Oct 5, 2026 Insider
Rubino Ivana was granted 80,000 shares
Chief Commercial Officer
Sep 1, 2026 Press
ProMIS Neurosciences announced its participation in five investor conferences in September 2026, including a fireside…
Impact 3/10
Aug 5, 2026 Insider
Kaplan Johanne bought 2,280 shares
Chief Development Officer @ $13.30 ($30.3K)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
56,045 shares ($737.6K)
Jun 30, 2026 Inst.
UBS Group AG — TRIM
691 shares ($9.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
PMN Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 6, 2026
Announcement
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and…
Sep 1, 2026
Announcement
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing…
Aug 13, 2026
Announcement
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused…
Aug 13, 2026
Earnings date
PMN Q2 2026 Earnings Scheduled — 2026-08-13
Aug 11, 2026
Earnings date
PMN Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

5 filings · 4 press releases · 0 bullish · 3 bearish · 2 neutral
All PMN filing & press-release reports (9)